Progress in Neuro-psychopharmacology and Biological Psychiatry
February 27, 2026
Chris H. Miller, Angela Hickman, Caitlin Baten et al.
2 citations
Ketamine pharmacotherapy provides a novel treatment option for major depressive disorder (MDD) and has generated a large, growing body of research regarding its biochemical and clinical properties. This narrative review summarizes the history of ketamine's development, beginning as a general anesthetic, continuing with a discovery of its antidepressant properties, and leading up to its landmark...
Biological psychiatry. Cognitive neuroscience and neuroimaging
January 13, 2026
Caitlin Baten, Gladys Zamora, Amanda M. Klassen et al.
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder with limited treatment success in both youth and adults. Functional magnetic resonance imaging (fMRI) studies have reported partially differential patterns of activation in youth and adults diagnosed with MDD that may be attributable to age or length of illness. Following PRISMA guidelines, we searched PubMed through...
European Psychiatry
April 1, 2024
Amanda M. Klassen, Caitlin Baten, J. H. Shepherd et al.
Introduction Major depressive disorder (MDD) is a tremendous global disease burden and the leading cause of disability worldwide. Unfortunately, individuals diagnosed with MDD typically experience a delayed response to traditional antidepressants and many do not adequately respond to pharmacotherapy, even after multiple trials. The critical need for novel antidepressant treatments has led to a...
European Psychiatry
April 1, 2024
J. H. Shepherd, Angela Hickman, Caitlin Baten et al.
Introduction There has been rapidly growing interest in understanding the pharmaceutical and clinical properties of psychedelic and dissociative drugs, with a particular focus on ketamine. This compound, long known for its anesthetic and dissociative properties, has garnered attention due to its potential to rapidly alleviate symptoms of depression, especially in individuals with...